Pancreatic cancer is relatively uncommon compared to cancers like breast, lung, or colon cancer, with roughly 60,000 new cases diagnosed per year in the United States. But it is far deadlier than its numbers suggest. Despite accounting for only about 3% of all new cancer diagnoses, it ranks among the top causes of cancer-related death, and projections suggest it will become the second leading cause of cancer death by 2030.
How Common It Actually Is
About 60,000 Americans are diagnosed with pancreatic cancer each year, out of an estimated 2 million total new cancer cases annually. That puts it well behind the most frequently diagnosed cancers. For comparison, breast cancer alone accounts for roughly 300,000 new cases per year, and lung cancer about 230,000. By raw numbers, pancreatic cancer is not something most people will encounter.
Yet calling it “rare” can be misleading. In the medical world, a rare disease is typically defined as one affecting fewer than 200,000 people at any given time. Pancreatic cancer hovers near that threshold, largely because so few patients survive long enough to be counted among those currently living with the disease. The low survival rate keeps prevalence numbers artificially small, even as the number of new diagnoses each year continues to climb.
Why It’s So Deadly Despite Low Numbers
The gap between how often pancreatic cancer is diagnosed and how many people it kills is striking. More than half of all cases, about 51%, are not caught until the cancer has already spread to distant organs. At that stage, the five-year survival rate is just 3.2%. Even when the cancer has spread only to nearby lymph nodes, survival drops to about 16.7%.
Only 15% of pancreatic cancers are found while still confined to the pancreas. Those patients have a much better outlook, with a five-year survival rate of roughly 44%. But catching it that early is the exception, not the rule, because the pancreas sits deep in the abdomen and early-stage tumors rarely cause noticeable symptoms.
No Routine Screening Exists
One major reason pancreatic cancer is caught so late is that there is no standard screening test for the general population. The U.S. Preventive Services Task Force has recommended against screening asymptomatic adults, both in 2004 and again in 2019. The reasoning is straightforward: the cancer’s relatively low incidence means screening large numbers of healthy people would produce too many false alarms, leading to unnecessary procedures and anxiety without a clear survival benefit.
This is fundamentally different from cancers like colon or breast cancer, where proven screening tools (colonoscopies, mammograms) catch disease early in millions of people. For pancreatic cancer, the math simply doesn’t work for average-risk individuals. Screening efforts are instead focused on people at higher risk.
Who Faces a Higher Risk
Certain genetic mutations and family history patterns significantly raise a person’s lifetime risk. Screening guidelines from the American Society for Gastrointestinal Endoscopy identify several groups who should be monitored, including carriers of mutations in genes like BRCA1, BRCA2, PALB2, and CDKN2A. People with two or more blood relatives who have had pancreatic cancer also qualify for surveillance.
Some inherited conditions carry enough risk that screening is recommended starting at age 35 to 40. These include Peutz-Jeghers syndrome, familial atypical multiple mole melanoma syndrome, and hereditary pancreatitis. For BRCA1 and BRCA2 carriers, updated guidelines now recommend pancreatic cancer screening regardless of family history, a change from earlier recommendations that required a relative with the disease.
Different Types, Different Rarity
Not all pancreatic cancers are the same. About 93% are pancreatic adenocarcinoma, which starts in the cells lining the pancreatic ducts. This is the type most people mean when they say “pancreatic cancer,” and it carries the grim survival statistics described above.
The remaining 7% are pancreatic neuroendocrine tumors, which arise from hormone-producing cells. These are genuinely rare and tend to behave quite differently. They often grow more slowly and carry a better prognosis, though outcomes vary widely depending on the tumor’s grade and whether it has spread.
A Growing Problem
While pancreatic cancer is not common today, it is becoming more so. Research projecting cancer trends through 2030 found that pancreatic cancer is expected to surpass breast, prostate, and colorectal cancers as a cause of cancer death, rising to the second leading cause behind only lung cancer. This shift reflects both the aging population and the fact that survival gains for pancreatic cancer have lagged far behind progress in other cancers.
So the short answer to whether pancreatic cancer is rare depends on what you’re measuring. It is uncommon in terms of how many people are diagnosed each year. It is disproportionately common in terms of how many people it kills. And by most projections, both of those numbers are heading in the wrong direction.